Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;20(11):629-644.
doi: 10.1038/s41568-020-0295-5. Epub 2020 Sep 9.

Hyperinsulinaemia in cancer

Emily J Gallagher  1   2 , Derek LeRoith  3   4
Affiliations
Review

Hyperinsulinaemia in cancer

Emily J Gallagher et al. Nat Rev Cancer. 2020 Nov.

Abstract

Elevated circulating insulin levels are frequently observed in the setting of obesity and early type 2 diabetes, as a result of insensitivity of metabolic tissues to the effects of insulin. Higher levels of circulating insulin have been associated with increased cancer risk and progression in epidemiology studies. Elevated circulating insulin is believed to be a major factor linking obesity, diabetes and cancer. With the development of targeted cancer therapies, insulin signalling has emerged as a mechanism of therapeutic resistance. Although metabolic tissues become insensitive to insulin in the setting of obesity, a number of mechanisms allow cancer cells to maintain their ability to respond to insulin. Significant progress has been made in the past decade in understanding the insulin receptor and its signalling pathways in cancer, and a number of lessons have been learnt from therapeutic failures. These discoveries have led to numerous clinical trials that have aimed to reduce the levels of circulating insulin and to abrogate insulin signalling in cancer cells. With the rising prevalence of obesity and diabetes worldwide, and the realization that hyperinsulinaemia may contribute to therapeutic failures, it is essential to understand how insulin and insulin receptor signalling promote cancer progression.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lauby-Secretan, B. et al. Body fatness and cancer — viewpoint of the IARC Working Group. N. Engl. J. Med. 375, 794–798 (2016). This statement from the IARC Working Group discusses the relative risks of cancer with obesity. - PubMed - PMC
    1. Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350, g7607 (2015). - PubMed
    1. Pearson-Stuttard, J. et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 6, e6–e15 (2018). - PubMed - PMC
    1. Morales Camacho, W. J. et al. Childhood obesity: aetiology, comorbidities, and treatment. Diabetes Metab. Res. Rev. 35, e3203 (2019). - PubMed
    1. Zhang, F. F. et al. Preventable cancer burden associated with poor diet in the United States. JNCI Cancer Spectr. 3, pkz034 (2019). - PubMed - PMC

MeSH terms

LinkOut - more resources